Skip to Main Content
Skip Nav Destination

Amphotericin B (Liposomal)



Amphotericin B (Liposomal)


(am foe TER i sin bee lye po SO mal)

Brand Names: US

  • AmBisome

Therapeutic Category

  • Antifungal Agent, Systemic

Medication Safety Issues

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Sound-alike/look-alike issues:

AmBisome may be confused with Ambisolm, Ambisom

Amphotericin B liposomal may be confused with amphotericin B

Other safety concerns:

Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (Amphocin, Fungizone) or with other lipid-based amphotericin formulations (Abelcet, Amphotec)

Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.

This item requires a subscription. For full access to this content, please log in to an existing user account or purchase an individual subscription. If you have an active subscription and appear logged in (your name appears in the upper right corner), but you cannot access content, please click the “Log Out” option under your name and log back in.
Close Modal

or Create an Account

Close Modal
Close Modal